RxDoctor Payments Data

Juan Hernandez, MD

Internal Medicine · Lufkin, TXNPI 1154640001

Payments from drug & device makers

$2,391in general payments, 2019–2025

Across 122 payments — averaging $19.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$932
  • Novo Nordisk$394
  • Boehringer Ingelheim$299
  • Lilly USA, LLC$199
  • Bayer$148
  • Pfizer$104
  • plus $316 from 12 others

What the payments were for

  • Food & beverage$2,31497%
  • Education$783%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,391 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$76,948
Medicare patients
159
Services billed
1,130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide113$136,704
JardianceEmpagliflozin92$76,543
Synjardy XrEmpagliflozin/Metformin Hcl90$76,532
JanumetSitagliptin Phos/Metformin Hcl108$73,683
FarxigaDapagliflozin Propanediol86$64,884
JanuviaSitagliptin Phosphate62$59,006
Xigduo XrDapaglifloz Propaned/Metformin54$48,348
Tresiba Flextouch U-200Insulin Degludec30$42,711
EliquisApixaban40$40,161
NeurontinGabapentin14$34,876
TrulicityDulaglutide20$23,941
Janumet XrSitagliptin Phos/Metformin Hcl32$23,903
TradjentaLinagliptin32$19,804
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$19,480
MounjaroTirzepatide16$16,486

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Synjardy$299$180,284235 claims
MerckJanumet, Januvia, Janumet Xr, Lagevrio (Eua)$33$165,215217 claims
Novo NordiskOzempic, Rybelsus$394$149,600127 claims
AstraZenecaFarxiga, Nexium$932$76,191103 claims
Lilly USA, LLCTrulicity, Mounjaro$199$40,42736 claims
PfizerEliquis$104$40,16140 claims
AbbVieLinzess$32$10,88121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Lufkin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →